Please login to the form below

Not currently logged in
Email:
Password:

Biotech IPOs

This page shows the latest Biotech IPOs news and features for those working in and with pharma, biotech and healthcare.

Mega-mergers dominate as buoyant markets lift biopharma

Mega-mergers dominate as buoyant markets lift biopharma

These trends have been dampened down by bullish stock markets, which have helped biotech raise $2bn in IPOs in the second quarter alone. ... The biotech has also managed to increase its share price since its launch, a feat not frequently achieved in the

Latest news

  • Chi-Med goes for third IPO in Hong Kong Chi-Med goes for third IPO in Hong Kong

    It will be the third public listing for the biotech after earlier IPOs on the Nasdaq and London Stock Exchange, and the proceeds will be used to accelerate its late-stage ... The current pace of development of the biotech ecosystem in China is remarkable,

  • Investments show UK biotech still booming despite Brexit Investments show UK biotech still booming despite Brexit

    However not all the signs were positive. Public markets were quiet for biotech around the world, with only 19 IPOs globally, and none in the UK. ... This reflects a continuing shift away from biotech IPOs on European markets, with European biotech firms

  • Alector kicks off next wave of biotech IPOs Alector kicks off next wave of biotech IPOs

    US biotech raising money again. The US government shutdown of 35 days had deterred new IPOs in biotech, but market launches have now resumed with immune-neurology specialists Alector. ... A third IPO expected this week is from Gossamer, a San Diego-based

  • After December slump, what’s in store for biotech in 2019? After December slump, what’s in store for biotech in 2019?

    2018 was a bumper year for biotech investment and particularly IPOs, with 58 new listings crowned by Moderna’s record-breaking $604m offering and an escalation in the number of private ... Nevertheless, Renaissance says biotech IPOs “have been

  • Circassia seeks shift to AIM after failing LSE criteria Circassia seeks shift to AIM after failing LSE criteria

    so Circassia’s failure to stay on the main exchange undermines that view at a time when US biotech IPOs are running at their highest level for many years. ... The UK biotech insists there are benefits to moving to the AIM, including “lower

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    exchanges. Since trading kicked off this summer, the stock performance of some biotech start-ups has investors worried. ... While some might have seen Ascletis’ fate as a market correction to the biotech stock hype, further IPOs don’t seem to be

  • Pharma deals in July 2015 Pharma deals in July 2015

    According to the report by Evaluate and the BIA, there were only five biotech IPOs in the six-year period from 2008 to 2013. ... It is hoped that Immunocore and Mereo are signs that at long last the UK is attracting risk capital for biotech companies.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Last month we reported on a range of biotechs filing IPOs in the US. ... So despite a number of successful biotech IPOs early in the year the market conditions do seem to be toughening.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...